Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:NRXP OTCMKTS:PRVCF NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.67$0.66$0.49▼$2.75$60.11M1.88272,539 shs53,793 shsNRXPNRx Pharmaceuticals$3.21-1.8%$2.90$1.10▼$6.01$56.54M1.59421,045 shs169,264 shsPRVCFPreveCeutical Medical$0.02+6.7%$0.03$0.01▼$0.03$12.84M0.3440,065 shs21,452 shsUNCYUnicycive Therapeutics$5.01-4.6%$6.12$2.02▼$11.00$66.36M1.89277,342 shs808,621 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+6.03%+2.31%+0.24%-14.10%-66.50%NRXPNRx Pharmaceuticals-2.68%-1.21%-10.41%+59.51%+38.56%PRVCFPreveCeutical Medical-2.17%-13.13%-6.64%-4.66%+38.04%UNCYUnicycive Therapeutics-2.42%+13.27%-1.33%-4.13%+8.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTXContext Therapeutics2.571 of 5 stars3.63.00.00.00.01.71.3NRXPNRx Pharmaceuticals2.9899 of 5 stars3.64.00.00.02.60.80.6PRVCFPreveCeutical MedicalN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics3.3931 of 5 stars3.74.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 3.17Buy$5.50717.24% UpsideNRXPNRx Pharmaceuticals 3.20Buy$28.50782.08% UpsidePRVCFPreveCeutical Medical 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.33Buy$60.001,115.07% UpsideCurrent Analyst Ratings BreakdownLatest PRVCF, UNCY, NRXP, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.006/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.005/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.005/16/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.004/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/APRVCFPreveCeutical MedicalN/AN/AN/AN/A($0.01) per shareN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/A$0.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$26.73M-$0.31N/AN/AN/AN/A-29.78%-29.08%8/6/2025 (Estimated)NRXPNRx Pharmaceuticals-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)PRVCFPreveCeutical Medical-$940KN/A0.00∞N/AN/AN/AN/AN/AUNCYUnicycive Therapeutics-$36.73M-$5.10N/AN/AN/AN/A-277.30%-61.53%N/ALatest PRVCF, UNCY, NRXP, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025CNTXContext Therapeutics-$0.06N/AN/AN/AN/AN/A5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$1.40-$0.50+$0.90-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/APRVCFPreveCeutical MedicalN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A48.8148.81NRXPNRx PharmaceuticalsN/A0.220.22PRVCFPreveCeutical MedicalN/AN/AN/AUNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%NRXPNRx Pharmaceuticals4.27%PRVCFPreveCeutical MedicalN/AUNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics2.80%NRXPNRx Pharmaceuticals19.00%PRVCFPreveCeutical MedicalN/AUNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics789.70 million87.19 millionNot OptionableNRXPNRx Pharmaceuticals217.29 million14.00 millionOptionablePRVCFPreveCeutical MedicalN/A570.65 millionN/ANot OptionableUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionablePRVCF, UNCY, NRXP, and CNTX HeadlinesRecent News About These CompaniesUnicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8 at 3:01 PM | finanznachrichten.deUnicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price RecoveryJuly 8 at 8:49 AM | quiverquant.comQUnicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8 at 8:30 AM | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher - Time to Buy?July 8 at 3:32 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 7, 2025 | prnewswire.comUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 7, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY - MorningstarJuly 3, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 2, 2025 | prnewswire.comUnicycive hit with CRL on oxylanthanum carbonate NDAJuly 1, 2025 | thepharmaletter.comTKaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJuly 1, 2025 | theglobeandmail.comUnicycive Therapeutics, Inc. (UNCY) - Yahoo FinanceJune 30, 2025 | finance.yahoo.comFDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospectJune 30, 2025 | fiercepharma.comFUnicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemiaJune 30, 2025 | msn.comUnicycive stock falls after FDA issues Complete Response LetterJune 30, 2025 | investing.comUnicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate ApplicationJune 30, 2025 | marketwatch.comUnicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease ...June 30, 2025 | finance.yahoo.comUnicycive Shares Sink After FDA Issues Response Letter on Kidney Drug FilingJune 30, 2025 | msn.comINVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLCJune 30, 2025 | globenewswire.comUnicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 30, 2025 | globenewswire.comUnicycive Therapeutics Inc News (UNCY) - Investing.comJune 24, 2025 | investing.comUnicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?June 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVCF, UNCY, NRXP, and CNTX Company DescriptionsContext Therapeutics NASDAQ:CNTX$0.67 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.48%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.NRx Pharmaceuticals NASDAQ:NRXP$3.21 -0.06 (-1.83%) Closing price 04:00 PM EasternExtended Trading$3.32 +0.11 (+3.55%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.PreveCeutical Medical OTCMKTS:PRVCF$0.02 +0.00 (+6.67%) As of 03:34 PM EasternPreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.Unicycive Therapeutics NASDAQ:UNCY$5.01 -0.24 (-4.57%) Closing price 04:00 PM EasternExtended Trading$5.01 +0.00 (+0.02%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
